Lung Cancer Management
Scope & Guideline
Exploring Innovations in Treatment and Research
Introduction
Aims and Scopes
- Clinical Management of Lung Cancer:
The journal emphasizes research related to the diagnosis and treatment of lung cancer, including novel therapies, chemotherapy, and immunotherapy. It aims to provide insights into the best clinical practices for managing different types of lung cancer. - Health Economics and Cost Analysis:
Research on the economic implications of lung cancer diagnosis and treatment is a core focus. This includes studies on cost differences between healthcare systems and the financial burden of lung cancer on patients and healthcare providers. - Biomarkers and Genetic Research:
The journal highlights studies that explore the role of biomarkers and genetic mutations in lung cancer, particularly in relation to targeted therapies and personalized medicine. - Patient Quality of Life and Supportive Care:
A significant area of focus is on the quality of life for lung cancer patients, including studies on symptom management, psychological support, and the impact of lung cancer on daily living. - Public Health and Screening Initiatives:
The journal also addresses public health issues, such as disparities in lung cancer screening and the implementation of screening programs to improve early detection.
Trending and Emerging
- Precision Medicine and Targeted Therapies:
There is an increasing focus on precision medicine, particularly studies evaluating the efficacy of targeted therapies for specific genetic mutations in lung cancer, such as ALK and EGFR. This trend signifies a move towards more personalized treatment plans. - Impact of COVID-19 on Lung Cancer Care:
Research examining the implications of the COVID-19 pandemic on lung cancer diagnosis and treatment has emerged as a significant theme, highlighting challenges in patient care during global health crises. - Real-World Evidence and Outcome Studies:
There is a growing emphasis on real-world evidence and outcomes in lung cancer treatment, focusing on the effectiveness of therapies in diverse populations and settings, which is crucial for informing clinical guidelines. - Quality of Life and Patient-Centered Care:
Studies addressing the quality of life for lung cancer patients and their psychological well-being are gaining more attention, emphasizing the importance of holistic care in cancer management. - Health Disparities and Screening Initiatives:
Research focused on health disparities among different populations and the effectiveness of lung cancer screening initiatives is increasingly prevalent, reflecting a commitment to improving access and outcomes in lung cancer care.
Declining or Waning
- Traditional Chemotherapy Approaches:
There has been a noticeable decrease in research focused on traditional chemotherapy methods, with more emphasis now placed on targeted therapies and immunotherapy. This reflects the evolving treatment landscape and the growing preference for personalized medicine. - Basic Science Research:
Research that focuses purely on basic science aspects of lung cancer, such as cell biology or preclinical studies, appears to be waning. The journal is increasingly prioritizing clinical outcomes and real-world evidence. - Generalized Treatment Protocols:
Studies that discuss generalized treatment protocols without incorporating specific patient demographics or genetic profiles are less frequently published. The trend is moving towards more tailored approaches that consider individual patient characteristics.
Similar Journals
Canadian Journal of Respiratory Critical Care and Sleep Medicine
Shaping the future of respiratory and critical care medicine.Welcome to the Canadian Journal of Respiratory Critical Care and Sleep Medicine, a prestigious peer-reviewed journal published by Taylor & Francis Inc. With an ISSN of 2474-5332 and an E-ISSN of 2474-5340, this journal serves as a vital platform for disseminating cutting-edge research in the fields of critical care, intensive care medicine, and pulmonary and respiratory medicine. Since its inception in 2017, the journal has established itself within the academic community, currently holding a Q2 ranking in Critical Care and Intensive Care Medicine and a Q3 ranking in Pulmonary and Respiratory Medicine for 2023. Although it operates under a standard access model, the journal remains committed to providing valuable insights and advancing knowledge through rigorous research articles, reviews, and case studies. Positioned in the heart of the United States, the journal aims to foster collaboration and innovation among healthcare professionals, researchers, and students dedicated to enhancing respiratory care and critical treatment protocols. Join us in exploring the dynamic intersection of research and practice that defines our mission.
Molecular and Clinical Oncology
Uncovering the molecular secrets of oncology.Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.
Current Pulmonology Reports
Exploring the latest innovations in pulmonology.Current Pulmonology Reports, published by SPRINGER, stands as a vital resource in the realm of respiratory health, delivering peer-reviewed research that informs clinical practices and advances understanding within the field of pulmonology. With an E-ISSN of 2199-2428, this journal captures the latest findings and technological innovations pertinent to respiratory diseases, treatment protocols, and patient management strategies. Although currently classified as non-open access, it ensures robust dissemination of significant research contributions which are essential for professionals and scholars alike. The journal's objective is not only to foster a deeper understanding of lung health issues but also to bridge the gap between research and application, thereby impacting real-world practices. As the demand for comprehensive studies in pulmonology continues to grow, Current Pulmonology Reports seeks to maintain its position as a premier outlet for quality research, ultimately bettering outcomes in respiratory medicine.
EUROPEAN RESPIRATORY JOURNAL
Exploring Innovations in Respiratory ResearchThe EUROPEAN RESPIRATORY JOURNAL, published by EUROPEAN RESPIRATORY SOC JOURNALS LTD, is at the forefront of advancing knowledge in the fields of pulmonary and respiratory medicine. With its ISSN 0903-1936 and E-ISSN 1399-3003, this esteemed journal has established itself as a leading platform since its inception in 1988, currently converging towards 2024. Ranked in the Q1 category for both Medicine (miscellaneous) and Pulmonary and Respiratory Medicine in 2023, it stands as the 3rd of 155 journals in its field, reflecting an impressive 98th percentile Scopus ranking. The journal boasts a rigorous selection of peer-reviewed articles that encompass innovative research, clinical studies, and reviews, thereby enhancing the understanding and treatment of respiratory diseases. Although it does not currently offer an Open Access option, the journal remains crucial for researchers, clinicians, and healthcare professionals committed to improving respiratory health across Europe and beyond. Join a community dedicated to groundbreaking research and advancements in respiratory medicine.
Clinical Genitourinary Cancer
Transforming insights into clinical practice.Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.
Current Problems in Cancer: Case Reports
Advancing oncology through shared case insights.Current Problems in Cancer: Case Reports is a prominent scholarly journal published by Elsevier, focusing on critical case reports within the field of oncology. Since its transition to Open Access in 2020, it has enhanced accessibility for researchers and healthcare professionals seeking to share and discuss unique clinical scenarios and insights that advance cancer treatment and patient care. Operating from the United States, this journal aims to address the important and often intricate challenges faced in oncology, facilitating a platform for knowledge exchange and the exploration of new perspectives in cancer management. Despite its current Q4 category ranking in the 2023 oncology category of Scopus with a rank of #359/404, its goal is to enrich the academic discourse by featuring diverse case reports and promoting evidence-based practices. As the journal evolves from 2021 to 2024, it seeks to impact the field by inviting researchers, professionals, and students to contribute their findings, ultimately fostering a collaborative environment for tackling the complexities of cancer.
ACTA ONCOLOGICA
Elevating standards in oncology research and practice.ACTA ONCOLOGICA is a prestigious multidisciplinary journal published by Medical Journal Sweden AB, dedicated to advancing cancer research and clinical practice. As a key resource in the field of oncology, the journal aims to publish high-quality articles that cover significant developments in cancer biology, treatment modalities, and innovative imaging techniques. With an ISSN of 0284-186X and an E-ISSN of 1651-226X, ACTA ONCOLOGICA operates in the United Kingdom and is recognized for its substantial impact, currently holding a Q2 ranking in the categories of Hematology, Medicine (miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging in 2023. The journal’s commitment to disseminating pivotal research is reflected in its inclusion in Scopus, with rankings placing it in the top half of its fields. Though it does not currently offer Open Access, it remains an essential resource for researchers, healthcare professionals, and students seeking to stay informed on the latest trends and findings in oncology. Established in 1963, the journal continues to be a cornerstone of cancer research well into 2024.
ONCOLOGY REPORTS
Fostering Excellence in Cancer ResearchOncology Reports is a distinguished journal dedicated to advancing knowledge in the field of oncology. Published by Spandidos Publications Ltd, this journal has been a cornerstone in cancer research since its establishment in 1994 and is set to continue its impactful contributions until 2024. With ISSN 1021-335X and E-ISSN 1791-2431, it ranks in the Q2 category in Cancer Research, Medicine (Miscellaneous), and Oncology as of 2023, reflecting its solid standing in the academic community. The journal's current Scopus rankings position it notably within Medicine (Oncology) (#74/404, 81st percentile) and Biochemistry, Genetics and Molecular Biology (Cancer Research) (#67/230, 71st percentile), underscoring its rigorous peer-review process and the quality of its published research. Although not an open-access journal, Oncology Reports remains committed to disseminating vital information to researchers, professionals, and students, ensuring they stay at the forefront of developments in cancer studies. Its comprehensive scope promotes a multidisciplinary approach, encompassing clinical and experimental aspects of oncology, thus serving as an essential resource for those striving to understand and combat cancer.
Cancer Management and Research
Elevating patient outcomes through collaborative research.Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.
Oncology Research and Treatment
Shaping the landscape of cancer treatment and research.Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.